These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 30234387)
41. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Yutaka T; Ito S; Ohigashi H; Naohiro M; Shimono J; Souichi S; Teshima T Leuk Lymphoma; 2015; 56(11):3216-8. PubMed ID: 25760636 [No Abstract] [Full Text] [Related]
42. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970 [No Abstract] [Full Text] [Related]
43. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554 [TBL] [Abstract][Full Text] [Related]
44. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194 [TBL] [Abstract][Full Text] [Related]
45. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247 [TBL] [Abstract][Full Text] [Related]
47. A rare case of gastric MALT lymphoma resistant to multiple treatment regimens. Dong G; Huang Y; Yan Q; Chanudet E; Ye H; Liu H; Isaacson PG; Rodriguez-Justo M; Du MQ J Clin Pathol; 2012 Nov; 65(11):1049-50. PubMed ID: 22821913 [No Abstract] [Full Text] [Related]
48. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Lévy M; Copie-Bergman C; Amiot A; Dupuis J; Le Baleur Y; Belhadj K; Hémery F; Sobhani I; Delfau-Larue MH; Leroy K; Haioun C; Delchier JC Leuk Lymphoma; 2013 May; 54(5):940-4. PubMed ID: 22978684 [TBL] [Abstract][Full Text] [Related]
49. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437 [TBL] [Abstract][Full Text] [Related]
50. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA Leuk Lymphoma; 2017 Jul; 58(7):1589-1597. PubMed ID: 27838951 [TBL] [Abstract][Full Text] [Related]
51. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692 [TBL] [Abstract][Full Text] [Related]
52. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Park SI; Grover NS; Olajide O; Asch AS; Wall JG; Richards KL; Sobol AL; Deal AM; Ivanova A; Foster MC; Muss HB; Shea TC Br J Haematol; 2016 Oct; 175(2):281-289. PubMed ID: 27448091 [TBL] [Abstract][Full Text] [Related]
54. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242 [TBL] [Abstract][Full Text] [Related]
55. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma. Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181 [No Abstract] [Full Text] [Related]
56. Primary hepatic marginal zone lymphoma: A rare coincidence. Panda SS; Baisakh M; Panda A; Das H Curr Probl Cancer; 2018; 42(3):322-328. PubMed ID: 29519669 [TBL] [Abstract][Full Text] [Related]